16,947 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 16,947 shares of the company’s stock, valued at approximately $89,000.

A number of other institutional investors also recently bought and sold shares of the stock. Avity Investment Management Inc. raised its holdings in Corvus Pharmaceuticals by 138.2% in the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after purchasing an additional 16,000 shares during the period. Towerview LLC raised its holdings in Corvus Pharmaceuticals by 4.6% during the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after acquiring an additional 17,500 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals during the second quarter valued at about $44,000. Marshall Wace LLP bought a new stake in Corvus Pharmaceuticals during the second quarter valued at about $136,000. Finally, Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 10.6% during the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the period. 46.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRVS has been the topic of a number of recent analyst reports. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, Oppenheimer raised their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.83.

Corvus Pharmaceuticals Stock Up 0.1 %

Shares of Corvus Pharmaceuticals stock opened at $8.95 on Friday. The firm has a market cap of $575.13 million, a price-to-earnings ratio of -9.62 and a beta of 1.05. The business has a 50-day moving average price of $7.22 and a 200-day moving average price of $4.29. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $10.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.